How to buy Avenue Therapeutics stock (ATXI)

Avenue Therapeutics is a biotechnology business based in the US. Avenue Therapeutics shares (ATXI) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.80 – the same closing value as a week prior. Avenue Therapeutics employs 3 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Avenue Therapeutics stock

Buy Avenue Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Avenue Therapeutics stock price (NASDAQ: ATXI)

Use our graph to track the performance of ATXI stocks over time.

Avenue Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$1.80
52-week range	$1.60 - $26.47
50-day moving average more info button	$2.04
200-day moving average more info button	$4.41
Wall St. target price	$8.00
PE ratio more info button	0.0743
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$24.78

Is it a good time to buy Avenue Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Avenue Therapeutics price performance over time

Historical closes compared with the close of $1.84 from 2024-12-18

1 week (2024-12-13)	2.22%
1 month (2024-11-20)	-8.46%
3 months (2024-09-20)	-25.20%
6 months (2024-06-20)	-46.20%

1 year (2023-12-20)	1,177.78%
2 years (2022-12-20)	-98.14%
3 years (2021-12-20)	1028.925
5 years (2019-12-20)	8640

Is Avenue Therapeutics stock undervalued or overvalued?

Valuing Avenue Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Avenue Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Avenue Therapeutics's P/E ratio

Avenue Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Avenue Therapeutics shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Avenue Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-201.35%
Return on equity TTM	-535.1%
Profit margin	0%
Book value	$4.64
Market Capitalization more info button	$3.8 million

TTM: trailing 12 months

Avenue Therapeutics share dividends

We're not expecting Avenue Therapeutics to pay a dividend over the next 12 months.

Have Avenue Therapeutics's shares ever split?

Avenue Therapeutics's shares were split on a 1:75 basis on 25 April 2024 . So if you had owned 75 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Avenue Therapeutics shares – just the quantity. However, indirectly, the new 7400% higher share price could have impacted the market appetite for Avenue Therapeutics shares which in turn could have impacted Avenue Therapeutics's share price.

Avenue Therapeutics share price volatility

Over the last 12 months, Avenue Therapeutics's shares have ranged in value from as little as $1.6 up to $26.4675. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avenue Therapeutics's is -0.179. This would suggest that Avenue Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Avenue Therapeutics has bucked the trend.

Avenue Therapeutics overview

Avenue Therapeutics, Inc. , a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. .

Frequently asked questions

null
What percentage of Avenue Therapeutics is owned by insiders or institutions?
Currently 9.852% of Avenue Therapeutics shares are held by insiders and 10.333% by institutions. How many people work for Avenue Therapeutics?
Latest data suggests 3 work at Avenue Therapeutics. When does the fiscal year end for Avenue Therapeutics?
Avenue Therapeutics's fiscal year ends in December. Where is Avenue Therapeutics based?
Avenue Therapeutics's address is: 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154 What is Avenue Therapeutics's ISIN number?
Avenue Therapeutics's international securities identification number is: US05360L3042 What is Avenue Therapeutics's CUSIP number?
Avenue Therapeutics's Committee on Uniform Securities Identification Procedures number is: 05360L205